Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Bevacizumab in Primary Peritoneal High-Grade Serous Adenocarcinoma: NCT07213804 Clinical Landscape Report 2026
15 October 2026
NCT07213804 clinical landscape for Primary Peritoneal High-Grade Serous Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and dev…
9 min read
Fludarabine Phosphate in Acute Myeloid Leukemia: NCT07214064 Clinical Landscape Report 2026
15 October 2026
NCT07214064 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Metastatic Carcinoma to the Uterine Cervix: NCT07216703 Clinical Landscape Report 2026
15 October 2026
NCT07216703 clinical landscape for Metastatic Carcinoma to the Uterine Cervix: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq (Orca Bio) in Acute Myeloid Leukemia: NCT07216443 Clinical Landscape Report 2026
15 October 2026
NCT07216443 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PF-08049820 in Eczema: NCT07216027 Clinical Landscape Report 2026
15 October 2026
NCT07216027 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EVOLVE-104 in squamous cell carcinoma of the anus: NCT07217171 Clinical Landscape Report 2026
15 October 2026
NCT07217171 clinical landscape for squamous cell carcinoma of the anus: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
KT-621 in Dermatitis, Atopic: NCT07217015 Clinical Landscape Report 2026
15 October 2026
NCT07217015 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nogapendekin alfa inbakicept-pmln in Urothelial Carcinoma of the Urinary Bladder: NCT07217496 Clinical Landscape Report 2026
15 October 2026
NCT07217496 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
AZD-5335 in Folate Receptor Alpha-Positive, Platinum-Resistant Ovarian Cancer: NCT07218809 Clinical Landscape Report 2026
15 October 2026
NCT07218809 clinical landscape for Folate Receptor Alpha-Positive, Platinum-Resistant Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset c…
9 min read
Albumin-Bound Paclitaxel in Ovarian Cancer: CTRI/2025/10/096192 Clinical Landscape Report 2026
15 October 2026
CTRI/2025/10/096192 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fingolimod Hydrochloride in Multiple sclerosis relapse: NCT07220252 Clinical Landscape Report 2026
15 October 2026
NCT07220252 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vepugratinib in Neoplasm Metastasis: NCT07218380 Clinical Landscape Report 2026
15 October 2026
NCT07218380 clinical landscape for Neoplasm Metastasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.